We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Secukinumab 300 mg administered with an auto-injector ...

More patients with recently diagnosed psoriatic arthritis (PsA) saw clinical improvement by 3 months in a treat-to-target strategy with secukinumab, a monoclonal antibody targeting interleukin-17, ...

Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with secukinumab, which selectively ...